Wipfli Financial Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Wipfli Financial Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$3K	Buy	+39	New	+$3.29K	﹤0.01%	2242

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Wipfli Financial Advisors's XBI Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q3 2022: 39 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #2242 among its holdings.

704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

Wipfli Financial Advisors held 39 shares of State Street SPDR S&P Biotech ETF worth $3K as of Q3 2022.
State Street SPDR S&P Biotech ETF was a new Wipfli Financial Advisors position in Q3 2022.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2242 holding.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.